Seattle Genetics is a biotechnology company that focuses on the treatment of cancer. Seattle Genetics is the leader in developing antibody-drug conjugates (ADCs) which are a technology that sends cancer-fighting cells directly to the source. It was founded in 1998 by Clay B. Siegall, Ph.D. who is the company’s president, CEO, and chairman of the board. Siegall founded Seattle Genetics based on scientific innovation and rigorous research based on ADCs and the treatment of cancer cells.
Since it’s founding in 1998 Seattle Genetics has entered into multiple strategic licenses for their ADC development and they have generated over $325 to date. With Seattle Genetics new funding and money, they plan to create a diverse pipeline of proprietary ADCs to take the treatment of cancer one step further. Siegall and Seattle Genetics have been brought to the attention of many different journals and news outlets, one being Biz Journals where they discuss is an ambitious plan for twelve more drugs and the increase of employees to help work on the twelve new drugs.
Seattle Genetics is planning on focusing their continue research on Adcetris which is their only commercialized drug to date. Currently, they are performing seventy different trails with Adcetris but want to expand that to the next stage with more trails. With the expansion of trails and drug creation, it is allowing for Siegal to hire over one-hundred new employees.
Prior to Siegel’s role in co-founding Seattle Genetics, he was with Bristol-Myers Squibb Pharmaceutical Research Institute doing pharmaceutical research for over six years. It is no secret that Siegel is highly educated in the production of pharmaceutical drugs, and he has taken his expertise to tackle some of the most dangerous cells, cancer cells.